title: Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.
abstract: While psychoeducational strategies and general support are always indicated for the treatment of chronic fatigue syndrome (CFS), pharmacological strategies are yet not well established. Antidepressants such as selective serotonin re-uptake inhibitors have been shown to influence positively symptoms and immunological parameters. However, a considerable part of CFS patients do not satisfactorily respond to them. Bupropion, a centrally acting catecholamine-transporter blocker without classic psycho-analeptic properties, shows theoretical potential to improve fatigue symptoms. In the reported case paroxetine was augmented with bupropion at high dosage, a strategy which consecutively led to a rapid relief of CFS-symptoms.
authors.forename: C
authors.initials: C
authors.lastname: Schönfeldt-Lecuona
authors.forename: B J
authors.initials: BJ
authors.lastname: Connemann
authors.forename: R C
authors.initials: RC
authors.lastname: Wolf
authors.forename: M
authors.initials: M
authors.lastname: Braun
authors.forename: R W
authors.initials: RW
authors.lastname: Freudenmann
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D015673:Fatigue Syndrome, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D017374:Paroxetine / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion; D017374:Paroxetine